The p53 pathway is inactivated in most human cancers, and its reactivation in tumors appears as a promising therapeutic strategy. Overexpression of Mdm4, a p53 negative regulator, occurs in a significant fraction of human cancers. Mouse models were used to evaluate the therapeutic potential of strategies against Mdm4, and encouraging results were obtained for tumor cells in which Mdm4 overexpression prevents wild-type p53 to exert its tumor suppressive functions. However, missense mutations in the p53 gene occur in about half of human cancers, and 15% of such mutations lead to the expression of a mutant protein that retains partial activity. In this report, we used mouse models to address the therapeutic potential of strategies against Mdm4 in tumors expressing an hypomorphic p53 mutant. We found that, in an Rb þ / À background promoting pituitary and thyroid tumors, decreased Mdm4 levels improved the survival of mice expressing wild-type p53, but not that of mice expressing p53 DP , a p53 hypomorph lacking the proline-rich domain. Importantly, however, most Rb þ / À p53 DP/DP mice developped pituitary adenomas, but these tumors were rare in Rb þ / À p53 DP/DP Mdm4 À / À animals, because Mdm4 loss led to increased p21 levels, a suppressor of pituitary tumor growth. On the contrary, Rb þ / À p53 DP/DP and Rb þ / À p53 DP/DP Mdm4 À / À mice developped anaplastic thyroid carcinomas at equal frequencies. Importantly, wild-type p53 represses the Plk1 gene, which encodes a promising therapeutic target in anaplastic thyroid carcinomas, and this repression is improved when Mdm4 levels are decreased. On the opposite, p53
INTRODUCTION
The p53 pathway is altered in most, if not all human tumors. Mutations in TP53, the gene encoding p53, are found in about half of human cancers, and at least 20% of the other tumors present an overexpression or an amplification of Mdm2 or Mdm4 (also known as Mdmx), which encode major negative regulators of p53. 1, 2 Strategies to reactivate p53 in tumors are thus attractive therapeutic approaches, because they might apply to a wide variety of cancers. In recent years, Mdm4 has emerged as a promising therapeutic target: reduced Mdm4 expression, achieved by decreasing Mdm4 gene dosage, or by using RNA interference or molecules that target Mdm4, were shown to suppress tumor growth in several studies. [3] [4] [5] [6] [7] [8] Most of these studies were performed in cancer cells expressing a wild-type p53 protein and overexpressing Mdm4, so that inhibiting Mdm4 in these cells allowed an efficient recovery of p53 tumor suppressive functions. However, about 15% of TP53 missense mutations in human cancers lead to the expression of a mutant p53 with partial activity. 1, 9 In this report, we wanted to determine if reducing Mdm4 levels in cells expressing an hypomorphic p53 mutant might improve tumor suppression and survival. We found that a decrease in Mdm4 levels improves the survival of mice expressing a wild-type p53, but is inefficient in mice expressing p53 DP , an hypomorphic mutant p53. Thus, although one should be careful about extrapolating these conclusions to human cancers, our results indicate that strategies against Mdm4 that work in cells expressing wild-type p53 may not work in cells expressing a p53 hypomorph. Furthermore, they suggest that the capacity of p53 to act as a transcriptional repressor should be taken into account when evaluating the therapeutic potential of strategies aimed at reactivating p53 in tumors.
RESULTS AND DISCUSSION
In order to determine if targeting Mdm4 may improve the survival of animals expressing an hypomorphic p53, we used mice expressing p53 DP , a p53 lacking its proline-rich domain.
3 p53
DP/DP mice appeared as a tool of choice for this study, because unlike wild-type mice, they are viable in an Mdm4-deficient background. The p53 DP protein is an inefficient transcriptional activator that has lost cell cycle control but retained a partial capacity to induce apoptosis. Although p53 DP does not model a specific human cancer mutant, most hypomorphic p53 mutants reported in human tumors appear, like p53 DP , to transactivate the proapoptotic Bax gene more efficiently than the cell cycle control gene p21 (Leroy et al. 10 and Supplementary Figure 1) . Previous experiments showed that p53 DP is a rather good suppressor of spontaneous tumors, because 90% of p53 DP/DP mice remained tumor-free after 1 year. On the contrary, experiments with tumor xenografts indicated that p53 DP is a poor suppressor of oncogene- induced tumors. 3 These observations led us to analyze the effects of Mdm4 loss on p53 DP in a Rb þ / À background to accelerate tumor onset, because germline Rb and p53 mutations were reported to exhibit cooperative tumorigenic effects. 11 To estimate the capacity of p53 DP/DP mice to suppress tumors in a Rb
background, we first compared survival curves and tumor spectra in Rb
mice. As shown previously, 11 we found that an haploinsufficiency or deficiency in p53 accelerates tumorigenesis in a Rb þ / À background, and that Rb þ / À and Rb þ / À p53 þ / À mice develop pituitary adenomas and thyroid carcinomas, whereas Rb
À / À mice developped the same tumors, but also the thymic lymphomas and sarcomas typical of p53-deficient animals (Figures 1a and b Figure 1a ). Furthermore, they developped pituitary adenomas and anaplastic thyroid carcinomas, but neither lymphomas nor sarcomas ( Figure 1b, Supplementary Figure 2) . In all the pituitary and thyroid tumors tested, p53 DP was still expressed ( Figure 1c ) and did not exhibit any mutation other than the deletion of the proline-rich domain (data not shown). Together, the results indicated that p53 DP exhibited a weak but significant capacity to delay tumor onset in a Rb þ / À background, suggesting that these genetic contexts were appropriate to evaluate the impact of decreased Mdm4 levels on an hypomorphic p53.
Next, we compared the survival of Rb
We observed that the loss of a single Mdm4 allele improved survival in a Rb þ / À background, but that the loss of one or both Mdm4 alleles had no impact on survival in a Rb þ / À p53 DP/DP context ( Figure 2a ). The only notable effect of decreased Mdm4 levels in a Rb þ / À p53 DP/DP background was a change in tumor spectrum in Mdm4-deficient animals; while thyroid tumors were as frequent with or without Mdm4, Mdm4 loss led to a significant decrease in pituitary adenomas (Figure 2b ). Previous analyses in mouse embryonic fibroblasts (MEFs) showed that Mdm4 loss improves the transactivating capacity of p53 DP , leading to increased levels of several p53 target genes, including the cyclin-dependent kinase inhibitor p21.
3 p21 is known to have a major role in the senescence limiting pituitary tumor 
þ / À and p53 DP/DP mice, described previously, 3, 21, 22 were intercrossed to generate cohorts of Rb
DP/DP mice, whose survival were followed for 650 days (cohort sizes are in parentheses). (b) The mice plotted in (a) were dissected when moribund or shortly after death and their tumors were classified. Tumor types could be assessed by gross necropsy, but a subset of each tumor type was confirmed histologically by using hematoxylin and eosin staining according to standard procedures. 23 All experiments were carried out according to IACUC regulations. (c) p53
DP is still expressed in pituitary and thyroid tumor cells from Rb þ / À p53 DP/DP mice. Total RNA, extracted using nucleospin RNA II (Macherey-Nagel, Dü ren, Germany), was reverse transcribed using superscript III (Invitrogen, Carlsbad, CA, USA). Real-time quantitative PCRs were performed on an ABI PRISM 7500 using Power SYBR Green (Applied Biosystems, Foster City, CA, USA) as recently described.
24 p53 mRNAs were quantified using real-time PCR, normalized to control mRNAs, then the amounts in tissues from p53 DP/DP mice were assigned a value of 1. 
DP/DP Mdm4 À / À mice over 650 days. Mdm4 þ / À mice, a kind gift from JC Marine, were described previously. 25 The loss of one Mdm4 allele extended the survival of Rb þ / À mice, but similar survival curves were observed in Rb þ / À p53 DP/DP mice, regardless of Mdm4 status. (b) Tumor types were assessed upon the necropsy of Rb
Mdm4 loss led to a three-fold decrease in the frequency of pituitary tumors, but had no effect on thyroid tumors. ***Pp0.001, NS: not significant by Student's t-test.
growth. 12 We thus hypothesized that pituitary tumors were less frequent in Rb
mice, because in the former group Mdm4 loss led to increased p21 levels in the pituitary gland. To test this, we dissected 7-month-old Rb þ / À p53 DP/DP and Rb þ / À p53 DP/DP Mdm4 À / À mice, and measured p21 mRNA levels in those pituitary glands that appeared normal upon dissection. Results, from five pituitary glands per group, revealed a two-fold increase in p21 mRNA levels in Mdm4-deficient animals ( Figure 3a) . Furthermore, when we used p21 À / À mice 13 to generate and compare cohorts of Rb
À / À mice, we found that Rb þ / À p53 DP/DP and Rb þ / À p53 DP/DP Mdm4 À / À p21 À / À mice had similar lifespans and tumor spectra (Figure 3b and Supplementary Figure 3) . Together, the data indicated that in these models Mdm4 loss limits tumor growth in the pituitary gland by activating p53 DP , leading to increased p21.
Importantly, the fact that Rb þ / À p53 DP/DP and Rb þ / À p53 DP/DP Mdm4 À / À mice had different tumor spectra but identical survival curves (Figure 2 ) suggested that the primary cause of death, for all animals, was the development of anaplastic thyroid carcinomas. Furthermore, because a Mdm4 haploinsufficiency improved survival in a Rb þ / À context but not in a Rb þ / À p53 DP/DP context, it was reasonable to assume that if decreased Mdm4 levels had no effect in the latter context it was due to an intrinsic defect of the mutant p53 DP protein.
To evaluate the functionality of p53 DP in thyroid tumors, we first quantified p21 mRNA levels in thyroids from Rb þ / À p53 DP/DP and Rb þ / À p53 DP/DP Mdm4 À / À animals, and found that the Mdm4 deficiency correlated with a two-fold increase in p21 levels (Supplementary Figure 4) . This indicated that p53 DP is still functional in thyroid tumors and that, as in pituitary tumors, its transactivation capacity can be increased by Mdm4 loss. Importantly however, p21 was found to have a major role in preventing pituitary, but not thyroid tumors. 12 Rather, the development of anaplastic thyroid carcinomas was correlated with an upregulation of a set of genes involved in the control of cell cycle progression and chromosome segregation.
14 Among these, the gene encoding polo-like kinase 1 (Plk1), a kinase with a pivotal role in mitosis, appears particularly important. Indeed, RNA interference or compounds against Plk1 caused the mitotic arrest of anaplastic thyroid carcinoma cells, suggesting that this protein might be a therapeutic target in thyroid carcinomas. 14, 15 Importantly, the binding of p53 at the promoter of Plk1 was shown to induce its repression, 16 leading us to evaluate if this gene was less efficiently repressed in cells expressing p53 DP than in cells expressing wild-type p53. Direct evidence for this was obtained by comparing WT and p53 DP/DP MEFs, before or after treatment with Nutlin, a specific Mdm2 inhibitor that enabled p53 activation; 17 we found that p53 DP was partially impaired in the repression of Plk1 (Figure 4a) . Furthermore, Mdm4 haploinsufficiency led to modest, but significant decreases in Plk1 mRNA levels in MEFs expressing WT p53, whereas the loss of both Mdm4 alleles had no impact on the repression of Plk1 in cells expressing p53 DP (Figure 4b ). Consistent with this, similar Plk1 mRNA levels were observed in tissues of Rb þ / À p53 DP/DP and Rb þ / À p53 DP/DP Mdm4 À / À mice, in both thyroid tumors (Figure 4c ) and other tissues (for example, Supplementary Figure 5) . Collectively, these results suggest that Mdm4 loss does not improve the survival of mice with Rb þ / À and p53 DP/DP mutations owing to, at least in part, a reduced capacity of p53 DP to mediate the transcriptional repression of Plk1, a gene important in thyroid tumorigenesis. Two non-exclusive mechanisms might contribute to make p53 DP a poor transcriptional repressor: (1) the mutant protein might be impaired in recruiting co-repressors such as mSin3a, known to interact with human p53 via the p53 proline-rich domain; 18, 19 (2) as an hypomorphic transactivator 
Mdm4
À / À animals. Total RNA were extracted as in Figure 1c from five pituitary glands of each genotype, then p21 mRNAs were quantified using real-time PCR, normalized to control mRNAs and the amounts in pituitary glands from Rb þ / À p53 DP/DP mice were assigned a value of 1. *Pp0.05 by Student's t-test. (b) Tumor types, assessed upon the necropsy of Rb DP/DP and p53 À / À embryos, then cultured in DMEM glutamax (Gibco, Gaithersburg, MD, USA), with 15% FBS (Biowest, Nuaillé , France), 100 mM 2-mercaptoethanol (Millipore, Billerica, MA, USA), 0.01 mM non essential amino-acids and penicillin/streptavidine (Gibco) in a 5% CO 2 and 3% O 2 incubator, and treated or not with 5 mM nutlin 3a 17 for 24 h, before RNA extraction and quantification by real-time QPCR. Nutlin activates p53, leading to a very efficient repression of Plk1 in WT cells, but a more modest repression in p53 DP/DP cells. ***Pp0.001 by Student's t-test. (b) Primary MEFs were prepared as above from 13.5 days old WT, Mdm4 þ / À , p53
DP/DP Mdm4 À / À and p53 À / À embryos, and Plk1 mRNAs were quantified by real-time PCR. The loss of one Mdm4 allele decreased Plk1 mRNA levels in cells expressing WT p53, but the loss of both Mdm4 alleles had no effect on Plk1 mRNA levels in cells expressing p53 
À / À mice, and mRNA levels in Rb þ / À p53 DP/DP tumors were assigned a value of 1. NS: not significant by Student's t-test.
Mdm4 loss in tumors expressing a p53 hypomorph M Fang et al p53 DP would induce p21 less efficiently, and p21 levels are known to contribute to the p53-mediated repression of many genes, 20 including Plk1 (Supplementary Figure 6) . The second possibility would imply that in a Rb þ / À p53 DP/DP context, p21 levels might be too low to enable efficient Plk1 repression even after Mdm4 loss.
In sum, we provide evidence that, depending on the tumor type, strategies against Mdm4 that are efficient in cells expressing a wild-type p53 may fail in cells expressing a mutant p53 with only partial functionality. In addition, our study suggests that the capacity of p53 to repress target genes should be considered in the evaluation of therapeutic anti-cancer strategies.
